Saniona
1.8 SEK +1.24%1 investor is following this company
Saniona is active in biotechnology. Today, research and development of drugs for the treatment of nerve diseases and other autoimmune diseases are conducted. The drug portfolio is broad and includes drugs that are currently in various clinical phases. Some of the work is also carried out in collaboration with other cooperation partners in the pharmaceutical industry. Saniona is headquartered in Glostrup.
Revenue
16.84M
EBIT %
-481.41 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SANION
Daily low / high price
1.764 / 1.858
SEK
Market cap
200.23M SEK
Turnover
254.38K SEK
Volume
141K
Latest videos
Financial calendar
General meeting
2024-05-25
Interim report
2024-05-29
Interim report
2024-08-29
Interim report
2024-11-28
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 7.4 % | 7.4 % |
Nordnet Pensionsförsäkring AB | 5.3 % | 5.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Saniona's CEO to BioStock: "Our development pipeline is stronger than ever"
Sanionas vd till BioStock: "Our development pipeline is stronger than ever"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools